Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Bayer begins Phase I study with GIRK4 inhibitor for atrial fibrillation

Bayer unveils drug for CKD associated with diabetes under brand name Kerendia

Ruchika Sharma26 Aug 2022 11:15 AM IST

The major focus of therapy in patients with chronic kidney disease and diabetes is to prevent end stage renal disease or kidney failure.

Combinations of 45 medicines fixed, including Sitagliptin- Metformin, Linagliptin -Metformin combinations

Ruchika Sharma25 Aug 2022 5:00 PM IST

New Delhi: Through a recent notice, The National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India...

Lupin to acquire diabetes brands Ondero, Ondero-Met from Boehringer Ingelheim for Rs 207 crore

Ruchika Sharma25 Aug 2022 3:30 PM IST

New Delhi: Lupin Limited is soon going to acquire two diabetes brands Ondero and Ondero - Met from Boehringer Ingelheim International GmbH for Rs...

Entresto Patent Expiry to Weigh on Novartis as Profit Seen Falling in 2026

Novartis Sandoz division to go independent

Ruchika Sharma25 Aug 2022 2:33 PM IST

The standalone Sandoz would be headquartered in Switzerland and listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in...

Dr Vivek Srivastava onboarded as Senior Vice President of Zeon Lifesciences

Ruchika Sharma25 Aug 2022 1:30 PM IST

New Delhi: Zeon Lifesciences, Indian manufacturer of nutraceuticals and herbal products announced the onboarding of Dr. Vivek Srivastava as a...

Lupin bags tentative USFDA nod for rare autoimmune disorder drug Amifampridine

Lupin, I'rom ink pact for biosimilar Denosumab

Ruchika Sharma25 Aug 2022 12:30 PM IST

Currently, Denosumab is available under two brands, Pralia and Ranmark.

Glenmark Pharma North Carolina facility gets USFDA OAI status

Ruchika Sharma25 Aug 2022 11:55 AM IST

Mumbai: Glenmark Pharmaceuticals Limited has recently announced that the company has received Official Action Indicated (OAI) status from the US Food...

Lupin gets USFDA nod for generic equivalent of Mylan Specialty Perforomist Inhalation Solution

Ruchika Sharma24 Aug 2022 5:00 PM IST

PERFOROMIST Inhalation Solution is a long-acting beta2-adrenergic agonist (beta2-agonist)

COVID vaccine 73.2 percent effective in children under 5: Pfizer

Ruchika Sharma24 Aug 2022 4:30 PM IST

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech's proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Bharat Biotech rotavirus oral vaccine ROTAVAC introduced in Nigeria for children

Ruchika Sharma24 Aug 2022 3:30 PM IST

Rotavirus is one of the leading causes of diarrheal disease in the world and is responsible for over 40% of diarrhoea in children.

AstraZeneca discontinues Phase 3 trial of prostate cancer drug Truqap

AstraZeneca may not stay in vaccine business in long run: CEO

Ruchika Sharma24 Aug 2022 2:57 PM IST

AstraZeneca is also looking for bolt-on acquisitions, including small and mid-sized companies specialising in oncology and cardiovascular treatments,...

Moderna seeks USFDA nod for COVID booster tailored against Omicron subvariants

Ruchika Sharma24 Aug 2022 1:15 PM IST

The submission also includes clinical trial data for its BA.1 Omicron-targeting bivalent booster candidate, which was last week cleared in Britain.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok